SYK Stock Recent News

Stryker (SYK) completes of the acquisition of MOLLI, a privately held company, to strengthen its commitment to advancing surgical solutions in breast cancer care.

Stryker is a global medical products and devices company that has global operations in over 75 countries. Historically, the company has been a compounder, generating high returns on capital and has put up impressive top and bottom line growth rates. Recent second quarter results showed strong growth in orthopedics and international markets, with a beat on both revenue and EPS.

While the top- and bottom-line numbers for Stryker (SYK) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Stryker (SYK) beats second-quarter earnings estimates, driven by robust sales growth and innovative launches like the LIFEPAK 35 and Spine Guidance 5. The company raises 2024 guidance.

Kevin Lobo, Stryker CEO, joins 'Money Movers' to discuss the company's second quarter earnings as it saw strong demand for surgical procedures and new products.

Here is how Stryker (SYK) and Centessa Pharmaceuticals PLC Sponsored ADR (CNTA) have performed compared to their sector so far this year.

SAN JOSE, California, USA, July 31, 2024 /PRNewswire/ -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today that it has completed the acquisition of MOLLI Surgical Inc., a privately held company specializing in the development of wire-free soft tissue localization technology for breast conserving surgery. MOLLI's portfolio further strengthens Stryker's commitment to advancing surgical solutions in breast cancer care.

Stryker Corporation (NYSE:SYK ) Q2 2024 Earnings Conference Call July 30, 2024 4:30 PM ET Company Participants Kevin Lobo - Chair and Chief Executive Officer Jason Beach - Vice President, Finance and Investor Relations Glenn Boehnlein - Vice President, Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JP Morgan Ryan Zimmerman - BTIG Joanne Wuensch - Citibank Travis Steed - Bank of America Matthew O'Brien - Piper Sandler Shagun Singh Chadha - RBC Matthew Miksic - Barclays Steve Lichtman - Oppenheimer Vijay Kumar - Evercore ISI Matthew Taylor - Jefferies Joshua Jennings - TD Cowen Danielle Antalffy - UBS Michael Matson - Needham Caitlin Cronin - Canaccord Jayson Bedford - Raymond James Andrew Ranieri - Morgan Stanley David Roman - Goldman Sachs Operator Welcome to the Second Quarter 2024 Stryker Earnings Call. My name is Luke, and I'm your operator for today's call.

Stryker Corp posted an upbeat second-quarter profit on Tuesday, as demand for its medical and surgical devices rose, driven by growth in non-urgent surgeries.

Stryker (SYK) came out with quarterly earnings of $2.81 per share, beating the Zacks Consensus Estimate of $2.79 per share. This compares to earnings of $2.54 per share a year ago.